Harry Erba, MD, PhD:So, next we’re going to discuss a 67-year-old woman who goes to her primary care physician with a number of symptoms. She has fatigue, she has abdominal fullness, she has night sweats, and she has been losing weight. She has lost 17 pounds. On her past medical history, she just has hypertension on physical exam. Her spleen tip is palpable, about 7 cm below the left costal margin. Nothing else on exam. In terms of her blood count, she’s anemic with a hemoglobin of 9.2. She has a normal platelet count of 189,000 and she has leukocytosis with a white-blood cell count of 19,000.
So, at that point, you know that the patient has leukocytosis anemia and a big spleen. There’s a very broad differential diagnosis here. And looking at the peripheral blood smear can be very helpful because this could be a patient with chronic lymphocytic leukemia, mantle cell lymphoma, or marginal zone lymphoma. So, lymphomas can present like this. Even hairy cell leukemia can present like this. And so, the peripheral blood smear might be very helpful with that leukocytosis if there are a lot of lymphocytes there and you can perform flow cytometry on the peripheral blood to try to ascertain the diagnosis. Evidently, that was likely not the case because she has a bone marrow biopsy, and the bone marrow biopsy shows class 3, or grade 3, fibrosis in the marrow, myelofibrosis. They do immunostains for CD34 and CD117 and find 1.2% blast in the marrow, and they do a molecular analysis showing that the disease in the marrow is positive for substitution of missense mutation inJAK2called the V617Fmutation. So, the final diagnosis is primary myelofibrosis.
Transcript edited for clarity.
March 2017
Rossetti Reviews Myelofibrosis Risk Stratification and Outcome Data for Pacritinib
July 17th 2024During a Case-Based Roundtable® event, James M. Rossetti, DO, discussed the role of risk scoring and stratification tools and treatment for a patient with declining hemoglobin and platelet counts due to primary myelofibrosis.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More
Ruxolitinib Treatment in Myelofibrosis Still Effective, Regardless of Anemia
June 21st 2024New or worsening anemia did not appear to reduce the clinical benefit of ruxolitinib in myelofibrosis patients, and the median overall survival was similar between patients with and without new or worsening anemia.
Read More
Challenging Disease Features of Myelofibrosis Lead to Use of JAK Inhibitors
June 17th 2024During a Case-Based Roundtable® event, Kristen Pettit, MD, moderated a discussion on which disease features of myelofibrosis are most challenging and when to use JAK inhibitors in the first article of a 2-part series.
Read More